The cancer drug developer emerged from stealth with $194m in funding, $85m of which was just closed in a round featuring returning investor Roche Venture Fund.
US-based precision oncology drug developer Black Diamond Therapeutics completed an $85m series C round yesterday that was backed by Roche Venture Fund, the corporate venturing subsidiary of pharmaceutical firm Roche.
The round was led by Boxer Capital and included Wellington Management, BVF Partners, Deerfield Management, Casdin Capital, Versant Ventures, New Enterprise Associates (NEA), Logos Capital, RA Capital Management, Nextech Invest, Invus, Perceptive Advisors, City Hill Ventures and funds managed by Janus Henderson Investors.
Founded in 2016 as Aset…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
